Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.

Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.

A cleaning composition including a) from about 1% to about 60% by weight of the composition of a surfactant system comprising an anionic surfactant and a primary co-surfactant selected from the group consisting of amphoteric surfactant, zwitterionic surfactant and mixtures thereof; and b) from about 0.001% to about 5% by weight of the composition of a class II hydrophobin.

A cleaning composition including a) from about 1% to about 60% by weight of the composition of a surfactant system comprising an anionic surfactant and a primary co-surfactant selected from the group consisting of amphoteric surfactant, zwitterionic surfactant and mixtures thereof; and b) from about 0.001% to about 5% by weight of the composition of a class II hydrophobin.

The present disclosure provides a composition comprising, (i) protein at a protein content of at least about 16% by dry weight, wherein at least about 50% by dry weight of the protein has an amino acid sequence encoded by one or more fungal genomes, and (ii) one or more materials selected from the group consisting of a flour, an oil, a flavoring agent, and a nutritional supplement, wherein the composition has a water content that is less than or equal to about 30% water by weight.

The present disclosure provides a composition comprising, (i) protein at a protein content of at least about 16% by dry weight, wherein at least about 50% by dry weight of the protein has an amino acid sequence encoded by one or more fungal genomes, and (ii) one or more materials selected from the group consisting of a flour, an oil, a flavoring agent, and a nutritional supplement, wherein the composition has a water content that is less than or equal to about 30% water by weight.

A protein provided is: a) a protein with an amino acid sequence as shown in amino acids 1-264 of SEQ ID NO: 1; b) a protein that is associated with disease resistance and obtained after an amino acid sequence as shown in amino acids 1-264 of SEQ ID NO: 1 in a Sequence Listing is subjected to substitution and/or deletion and/or addition of one or several amino acid residues; c) a protein with an amino acid sequence as shown in SEQ ID NO: 1; or d) a protein that is associated with disease resistance and obtained after the amino acid sequence as shown in SEQ ID NO: 1 in the Sequence Listing is subjected to substitution and/or deletion and/or addition of one or several amino acid residues. Experiments demonstrate that the protein associated with disease resistance and the encoding gene thereof can be used to enhance plant disease resistance.

A protein provided is: a) a protein with an amino acid sequence as shown in amino acids 1-264 of SEQ ID NO: 1; b) a protein that is associated with disease resistance and obtained after an amino acid sequence as shown in amino acids 1-264 of SEQ ID NO: 1 in a Sequence Listing is subjected to substitution and/or deletion and/or addition of one or several amino acid residues; c) a protein with an amino acid sequence as shown in SEQ ID NO: 1; or d) a protein that is associated with disease resistance and obtained after the amino acid sequence as shown in SEQ ID NO: 1 in the Sequence Listing is subjected to substitution and/or deletion and/or addition of one or several amino acid residues. Experiments demonstrate that the protein associated with disease resistance and the encoding gene thereof can be used to enhance plant disease resistance.

The present invention provides, for example, a set of two polypeptides exhibiting the nuclease activity with dependence on light or in the presence of a drug, in which an N-terminal side fragment and a C-terminal side fragment of a Cas9 protein are bound to each of two polypeptides which form a dimer with dependence on light or in the presence of a drug.

The present invention provides, for example, a set of two polypeptides exhibiting the nuclease activity with dependence on light or in the presence of a drug, in which an N-terminal side fragment and a C-terminal side fragment of a Cas9 protein are bound to each of two polypeptides which form a dimer with dependence on light or in the presence of a drug.